Advances in CAR T Therapy for Hematologic Malignancies.
acute lymphoblastic leukemia
chimeric antigen receptor
cytokine release syndrome
multiple myeloma
non-Hodgkin lymphoma
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
10
5
2020
medline:
4
6
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
The introduction of chimeric antigen receptor T-cell (CAR T) therapy has resulted in a paradigm shift in the management of relapsed/refractory B-cell malignancies. Patients with acute lymphoblastic leukemia and non-Hodgkin's lymphoma who had exhausted all meaningful treatment options now have an opportunity for long-term remission and possibly cure. CAR T is rapidly expanding into the treatment paradigm for multiple myeloma with approvals expected in the near future. CAR T for chronic lymphocytic leukemia may not be far behind, while CAR T studies in Hodgkin lymphoma and acute myeloid leukemia are ongoing. Such therapeutic success brings challenges in toxicity management related to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Our understanding of these unique syndromes is evolving, with predictive models and additional treatment strategies on the horizon. This review aims to summarize the progress of CAR T therapeutics within malignant hematology thus far and highlight ongoing advances in the field.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
741-755Informations de copyright
© 2020 Pharmacotherapy Publications, Inc.
Références
Maude SL, Laetsch TW, Buechner S, et al. Tisagenlecleucel in children and young adults with B cell lymphoblastic leukemia. New Engl J Med 2018;378:439-48.
Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B cell lymphoma. New Engl J Med 2019;380:45-56.
Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T cell therapy in refractory large B cell lymphoma. New Engl J Med 2017;377:2531-44.
Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019;20:31-42.
Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008;22:2142-50.
Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012;120:2032-41.
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130:1800-8.
Turtle CJ, Hanafi LA, Berger C, et al. CD 19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016;126:2123-38.
June CH, Sadelain M. Chimeric antigen receptor therapy. New Engl J Med 2018;379:64-73.
Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev 2016;30:157-67.
Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 2016;16:566-81.
Kymriah. [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Co.; 2017.
Porter DL, Frey NV, Wood PA, et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol 2018;11:81.
Grupp S, Hu ZH, Zhang Y, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory children and young adults with acute lymphoblastic leukemia (ALL) real world experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) registry. Blood 2019;134:2819.
Jaglowski S, Hu ZH, Zhang Y, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T cell therapy for adults with diffuse large B cell lymphoma (DLBCL): real world experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) registry. Blood 2019;134:766.
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625-38.
Yescarta. [Package insert]. Santa Monica, CA: Kite Pharma, Inc.; 2019.
Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188-95.
Pasquini MC, Locke FL, Herrera AF, et al. Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (axi-cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US). Blood 2019;134:764.
U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. Available from https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed December 10, 2019.
Riedell PA, Walling C, Nastoupil LJ, et al. A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Biol Blood Marrow Transplant 2020;26:S41.
Shah BD, Bishop MR, Oluwole OO, et al. End of phase 1 results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR)T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). J Clin Oncol 2019;37(suppl 15):7006.
Wayne AS, Huynh V, Hijiya N, et al. Phase 1 results of ZUMA-4: KTE-X19, an anti-CD19 chimeric receptor T cell therapy, in pediatric and adolescent patients with relapsed/refractory B cell acute lymphoblastic lymphoma. EHA Library. S. Wayne A. Jun 15, 2019; 267263; PS962. Available from https://library.ehaweb.org/eha/2019/24th/267263/alan.s.wayne.phase.1.results.of.zuma-4.kte-x19.an.anti-cd19.chimeric.antigen.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1. Accessed December 4, 2019.
Wang ML, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New Engl J Med 2020;382:1331-42.
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;25:740-53.
Pan J, Niu Q, Deng B, et al. CD22 CAR T cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 2019;33:2854-66.
Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naïve or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018;24:20-8.
Abramson JS, Palomba ML, Gordon L, et al. Pivotal safety and efficacy results from TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. Blood 2019;134:241.
Bachier CR, Palomba ML, Abramson JS, et al. Outpatient treatment with lisocabtagene maraleucel (liso-cel) in 3 ongoing clinical studies in relapsed/refractory (R/R) large B cell non-Hodgkin lymphoma (NHL), including second-line transplant noneligible (TNE) patients: TRANSCEND NHL 001, outreach, and PILOT. Biol Blood Marrow Transplant 2020;26:S25.
Rheingold SR, Chen LN, Maude SL, et al. Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to the CSF and induction of durable CNS remissions in children with CNS/combined relapsed/refractory ALL. Blood 2015;126:3769.
Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. New Engl J Med 2014;371:1507-17.
Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T cell therapy in secondary CNS lymphoma. Blood 2019;134:860-6.
Abramson JS, Palomba ML, Arnason JE, et al. Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: initial results from TRANSCEND NHL 001. J Clin Oncol 2019;37:7515.
Abramson JS, McGree B, Noyes S, et al. Anti-CD19 CAR T cells in CNS diffuse large-B cell lymphoma. New Engl J Med 2017;377:783-4.
Bennani NN, Maurer M, Nastoupil LJ, et al. Experience with axicabtagene ciloleucel (axi-cel) in patients with secondary CNS involvement: results from the US lymphoma CAR T consortium. Blood 2019;134:763.
Siddiqi T, Wang X, Palmer J, et al. CD19-targeting CAR-T cell therapy in CNS lymphoma. Blood 2019;134:4075.
Garfall AL, Stadtmauer EA, Hwang W-T, et al. T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 2019;4:1-14.
Zhao WH, Liu J, Wang BY, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol 2018;11:141.
Madduri D, Usumani SZ, Jagannath S, et al. Results from CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). Blood 2019;134:577.
Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 2019;380:1726-37.
Yan Z, Cao J, Cheng H, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 2019;6:e521-9.
Cowan AJ, Pont M, Sather BD, et al. Efficacy and safety of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma. Blood 2019;134:204.
Popat R, Zweegman S, Cavet J, et al. Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed/refractory multiple myeloma. Blood 2019;134:3112.
Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015;373:1207-19.
Li C, Mei H, Hu Y, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 for relapsed/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial. Blood 2019;134:930.
Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015;7:1-12.
Frey NV, Gill S, Hexner EO, et al. Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia. J Clin Oncol 2020;38 [in press].1-16.
Turtle CJ, Hay KA, Hanafi LA, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol 2017;35:3010-20.
Siddiqi T, Soumerai JD, Dorritie KA, et al. Rapid undetectable MRD (uMRD) responses in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T cell product: updated results from Transcend CLL 004, a phase 1/2 study including patients with high-risk disease previously treated with ibrutinib. Blood 2019;134:503.
Cox MJ, Lucien-Matteoni F, Sakemura R, et al. Circulating extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia (CLL). Biol Blood Marrow Transplant 2020;26:S2.
Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T cell engraftment and efficacy in leukemia. Blood 2016;127:1117-27.
Ruella M, Kenderian SS, Shestova O, et al. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B cell neoplasms. Leukemia 2017;31:246-48.
Gill SI, Vides V, Frey NV, et al. Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate. Blood 2018;132:298.
Gauthier J, Hirayama AV, Hay KA, et al. Efficacy and toxicity of CD19-specific chimeric antigen receptor T cells alone or in combination with ibrutinib for relapsed and/or refractory CLL. Biol Blood Marrow Transplant 2019;25:10.
Svoboda J, Rheingold SR, Gill SI, et al. Nonviral RNA with chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. Blood 2018;132:1022-6.
Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21.
Ramos CA, Bilgi M, Gerken CP, et al. CD30-chimeric antigen receptor (CAR) T cells for therapy of Hodgkin lymphoma (HL). Blood 2018;132:680.
Pemmaraju N, Lane MA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med 2019;380:1628-37.
Gill SI, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014;123:2343-54.
Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:1508-16.
Xue T, Del Real M, Marcucci E, et al. Checkpoint blockade in combination with CD33 chimeric antigen receptor T cell therapy and hypomethylating agent against acute myeloid leukemia. Blood 2019;134:1383.
Anwer F, Shaukat AA, Zahid U, et al. Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy 2017;9:123-30.
Ruella M, Kenderian SS. Next-generation chimeric antigen receptor T cell therapy: going off the shelf. BioDrugs 2017;32:473-81.
Wang N, Hu X, Cao W, et al. Efficacy and safety of CAR19/22 T cell “cocktail” therapy in patients with refractory/relapsed B cell malignancies. Blood 2020;135:17-27.
Schultz LM, Muffly LS, Spiegel JY, et al. Phase I trial using CD19/CD22 bispecific CAR T cells in pediatric and adult acute lymphoblastic leukemia (ALL). Blood 2019;134:744.
Sang W, Shi M, Yang J, et al. Combination of Anti-CD19 and Anti-CD20 chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma: an open-label, single-arm, phase I/II trial. Blood 2019;134:1590.
Byrne M, Oluwole OO, Savani B, et al. Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 2019;25:e344-51.
Chong EA, Svoboda J, Nasta SD, et al. Sequential anti-CD19 directed chimeric antigen receptor modified T cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B cell non-Hodgkin lymphomas. Blood 2018;132:4198.
Li AM, Hucks GE, Dinofia AM, et al. Checkpoint inhibitors augment CD19 directed chimeric antigen receptor (CAR) T cell therapy in relapsed B cell acute lymphoblastic leukemia. Blood 2018;132:556.
Jacobson CA, Locke FL, Miklos DB, et al. End of phase 1 results from ZUMA-6: axicabtagene ciloleucel (axi-cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2019;25:239.
Maude SL, Hucks GE, Callahan C, et al. Durable remissions with humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in CAR-naïve and CAR-exposed children and young adults with relapsed/refractory acute lymphoblastic leukemia. Blood 2017;130:1319.
Alvi RM, Frigault MJ, Fradley MG, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol 2019;74:3099-108.
Singh N, Hofmann TJ, Gershenson Z, et al. Monocyte lineage-derived Il-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy 2017;19:867-80.
Sterner RM, Sakemura R, Cox M, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T function in xenografts. Blood 2019;133:697-709.
Cox MJ, Kuhlmann C, Sterner RM, et al. Improved anti-tumor response after chimeric antigen receptor T cell (CART) therapy after GM-CSF inhibition is mechanistically supported by a novel direct interaction of GM-CSF with activated Carts. Biol Blood Marrow Transplant 2020;26:S60.
Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 2018;24:739-48.
Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016;6:664-79.
Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T cell therapy. Blood 2017;130:2295-306.
Frey NV, Shaw PA, Hexner EO, et al. Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol 2020;38:415-22.
Park JH, Riviere I, Gonen M, et al. Long-term follow up of CD19 CAR therapy in acute lymphoblastic leukemia. New Engl J Med 2018;378:449-59.
Myers RM, Kadauke S, Li Y, et al. Risk-adapted preemptive tocilizumab decreases severe cytokine release syndrome (CRS) after CTL019 CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (B-ALL). Biol Blood Marrow Transplant 2020;26:S39.
Locke FL, Neelapu SS, Bartlett NL, et al. Preliminary results of prophylactic tocilizumab after axicabtagene ciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL). Blood 2017;130:1547.
Park JH, Frigault MJ, Maziarz RT, et al. Trial in progress: a phase 2, single-arm, open-label study of itacitinib (ITA) for the prevent of chimeric antigen receptor (CAR) T-cell induced cytokine release syndrome (CRS). Biol Blood Marrow Transplant 2020;26:S269.
Actemra. [Package insert]. South San Francisco, CA: Genentech, Inc.; 2017.
Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018;23:943-47.
Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med 2017;45:e124-31.
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47-62.
Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open label, single-centre, pilot trial. Lancet Haematol 2019;6:e630-7.
Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 2016;44:275-81.
Sonmez HE, Demir S, Belinger Y, Ozen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol 2018;37:3329-35.
Mestermann K, Giavridis T, Weber J, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med 2019;11(499).1-11.
Weber EW, Lynn RC, Sotillo E, et al. Pharmacologic control of CAR-T function using dasatinib. Blood Adv 2019;3:711-17.
Frey NV, Porter DL. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 2019;25:e123-27.
DeAngelo DJ, Ghobadi A, Park JH, et al. Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study). J Immunother Cancer 2017;5:P217.
Gofshteyn JS, Shaw PA, Teachey DT, et al. Neurotoxicity after CTOL019 in a pediatric and young adult cohort. Ann Neurol 2018;84:537-46.
Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T cell therapy in patients with B cell acute lymphoblastic leukemia. Cancer Discov 2018;8:958-71.
Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 2017;7:1-16.
Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 2019;133:2212-21.
Topp MS, van Meerten T, Houot R, et al. Earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B cell lymphoma (R/R LBCL). Biol Blood Marrow Transplant 2020;26:S101.
Memorial Sloan Kettering Cancer Center. A study of anakinra to prevent or treat severe side effects for patients receiving CAR-T cell therapy. Available from https://www.clinicaltrials.gov/ct2/show/NCT04148430?term=anakinra+and+chimeric+antigen&draw=2&rank=2. Accessed March 27, 2020.
Kite Pharma. Study of lenzilumab and axicabtagene ciloleucel in participants with relapsed or refractory large B-cell lymphoma (ZUMA-19). Available from https://www.clinicaltrials.gov/ct2/show/NCT04314843?term=lenzilumab&draw=2&rank=2. Accessed March 27, 2020.
U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. Available from https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 10 December 2019.